Literature DB >> 29273848

Redox Imbalance in Intestinal Fibrosis: Beware of the TGFβ-1, ROS, and Nrf2 Connection.

Giovanni Latella1.   

Abstract

Intestinal fibrosis, a common complication of inflammatory bowel diseases, becomes clinically apparent in ~ 40% of patients with Crohn's disease and ~ 5% of those with ulcerative colitis. Fibrosis, a consequence of local chronic inflammation, is characterized by excessive deposition of extracellular matrix (ECM) proteins by activated myofibroblasts, which are modulated by pro-fibrotic and anti-fibrotic factors. Fibrosis depends on the balance between production and degradation of ECM proteins. Although the transforming growth factor (TGF)-β1/Smad pathway is the major driving force of fibrosis, several pro-fibrogenic and anti-fibrogenic endogenous factors appear to interact directly with this pathway such as reactive oxygen species (ROS) and nuclear factor-erythroid 2-related factor 2 (Nrf2), which are connected with TGF-β1 during fibrosis development in several organs, including the intestine. Nrf2 is a ubiquitous master transcription factor that upregulates the expression of antioxidant enzymes and cytoprotective proteins mediated by antioxidant response elements (AREs). Here, I describe and discuss the links among TGF-β1, ROS, and Nrf2-AREs in the pathogenesis of intestinal fibrosis.

Entities:  

Keywords:  Antioxidant response element (ARE); Colitis; Crohn’s disease; Fibrosis; Inflammatory bowel disease (IBD); Nrf2; Nuclear factor-erythroid-2-related factor 2 (NF-E2-related factor); Reactive oxygen species (ROS); TGF-β1/Smad pathway; miRNA

Mesh:

Substances:

Year:  2018        PMID: 29273848     DOI: 10.1007/s10620-017-4887-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  48 in total

Review 1.  TGF-β: the master regulator of fibrosis.

Authors:  Xiao-Ming Meng; David J Nikolic-Paterson; Hui Yao Lan
Journal:  Nat Rev Nephrol       Date:  2016-04-25       Impact factor: 28.314

2.  European Crohn's and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn's Disease.

Authors:  Florian Rieder; Giovanni Latella; Fernando Magro; Elif S Yuksel; Peter D R Higgins; Antonio Di Sabatino; Jessica R de Bruyn; Jordi Rimola; Jorge Brito; Dominik Bettenworth; Gert van Assche; Willem Bemelman; Andre d'Hoore; Gianluca Pellino; Axel U Dignass
Journal:  J Crohns Colitis       Date:  2016-02-29       Impact factor: 9.071

3.  miR-200b-containing microvesicles attenuate experimental colitis associated intestinal fibrosis by inhibiting epithelial-mesenchymal transition.

Authors:  Jia Yang; Cheng-Zhi Zhou; Rui Zhu; Heng Fan; Xing-Xing Liu; Xue-Yun Duan; Qing Tang; Zhe-Xing Shou; Dong-Mei Zuo
Journal:  J Gastroenterol Hepatol       Date:  2017-12       Impact factor: 4.029

Review 4.  MicroRNAs-mediated epithelial-mesenchymal transition in fibrotic diseases.

Authors:  Xiao-Zhou Zou; Ting Liu; Zhi-Cheng Gong; Chang-Ping Hu; Zheng Zhang
Journal:  Eur J Pharmacol       Date:  2016-12-02       Impact factor: 4.432

Review 5.  The molecular biology of matrix metalloproteinases and tissue inhibitors of metalloproteinases in inflammatory bowel diseases.

Authors:  Magali de Bruyn; Jennifer Vandooren; Estefania Ugarte-Berzal; Ingrid Arijs; Séverine Vermeire; Ghislain Opdenakker
Journal:  Crit Rev Biochem Mol Biol       Date:  2016-06-30       Impact factor: 8.250

6.  Smad3 loss confers resistance to the development of trinitrobenzene sulfonic acid-induced colorectal fibrosis.

Authors:  G Latella; A Vetuschi; R Sferra; G Zanninelli; A D'Angelo; V Catitti; R Caprilli; K C Flanders; E Gaudio
Journal:  Eur J Clin Invest       Date:  2009-02       Impact factor: 4.686

Review 7.  Results of the 4th scientific workshop of the ECCO (I): pathophysiology of intestinal fibrosis in IBD.

Authors:  Giovanni Latella; Gerhard Rogler; Giorgos Bamias; Christine Breynaert; Jon Florholmen; Gianluca Pellino; Shimon Reif; Silvia Speca; Ian C Lawrance
Journal:  J Crohns Colitis       Date:  2014-04-14       Impact factor: 9.071

8.  3-(2-Oxo-2-phenylethylidene)-2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(11bH)-one (compound 1), a novel potent Nrf2/ARE inducer, protects against DSS-induced colitis via inhibiting NLRP3 inflammasome.

Authors:  Yajing Wang; Hong Wang; Chen Qian; Jingjing Tang; Wei Zhou; Xiuting Liu; Qidong You; Rong Hu
Journal:  Biochem Pharmacol       Date:  2015-11-14       Impact factor: 5.858

9.  miR-200b is involved in intestinal fibrosis of Crohn's disease.

Authors:  Yingwei Chen; Wensong Ge; Leiming Xu; Chunying Qu; Mingjie Zhu; Wenzhu Zhang; Yongtao Xiao
Journal:  Int J Mol Med       Date:  2012-01-23       Impact factor: 4.101

10.  Implications of the colonic deposition of free hemoglobin-α chain: a previously unknown tissue by-product in inflammatory bowel disease.

Authors:  Jeremy N Myers; Michael W Schäffer; Olga Y Korolkova; Amanda D Williams; Pandu R Gangula; Amosy E M'Koma
Journal:  Inflamm Bowel Dis       Date:  2014-09       Impact factor: 7.290

View more
  18 in total

1.  Paediatric Ulcerative Colitis Is a Fibrotic Disease and Is Linked with Chronicity of Inflammation.

Authors:  Ilyssa O Gordon; Suha Abushamma; Jacob A Kurowski; Stefan D Holubar; Lei Kou; Ruishen Lyu; Florian Rieder
Journal:  J Crohns Colitis       Date:  2022-06-24       Impact factor: 10.020

2.  Inhibitory Effects of Momordicine I on High-Glucose-Induced Cell Proliferation and Collagen Synthesis in Rat Cardiac Fibroblasts.

Authors:  Po-Yuan Chen; Neng-Lang Shih; Wen-Rui Hao; Chun-Chao Chen; Ju-Chi Liu; Li-Chin Sung
Journal:  Oxid Med Cell Longev       Date:  2018-10-08       Impact factor: 6.543

3.  Transcription Factor ZNF281: A Novel Player in Intestinal Inflammation and Fibrosis.

Authors:  Maria Pierdomenico; Franscesca Palone; Vincenzo Cesi; Roberta Vitali; Anna Barbara Mancuso; Salvatore Cucchiara; Salvatore Oliva; Marina Aloi; Laura Stronati
Journal:  Front Immunol       Date:  2018-12-11       Impact factor: 7.561

Review 4.  Can Nrf2 Modulate the Development of Intestinal Fibrosis and Cancer in Inflammatory Bowel Disease?

Authors:  Simona Pompili; Roberta Sferra; Eugenio Gaudio; Angelo Viscido; Giuseppe Frieri; Antonella Vetuschi; Giovanni Latella
Journal:  Int J Mol Sci       Date:  2019-08-20       Impact factor: 5.923

Review 5.  PM2.5, Fine Particulate Matter: A Novel Player in the Epithelial-Mesenchymal Transition?

Authors:  Zihan Xu; Wenjun Ding; Xiaobei Deng
Journal:  Front Physiol       Date:  2019-11-29       Impact factor: 4.566

Review 6.  Targeting Nrf2 may reverse the drug resistance in ovarian cancer.

Authors:  Danjie Li; Xiaoling Hong; Feijie Zhao; Xinxin Ci; Songling Zhang
Journal:  Cancer Cell Int       Date:  2021-02-17       Impact factor: 5.722

7.  The Protective Role of Tanshinone IIA in Silicosis Rat Model via TGF-β1/Smad Signaling Suppression, NOX4 Inhibition and Nrf2/ARE Signaling Activation.

Authors:  Feifei Feng; Peng Cheng; Huanan Zhang; Nannan Li; Yuxin Qi; Hui Wang; Yongbin Wang; Wei Wang
Journal:  Drug Des Devel Ther       Date:  2019-12-18       Impact factor: 4.162

8.  Location and dynamic changes of inflammation, fibrosis, and expression levels of related genes in SiO2-induced pulmonary fibrosis in rats in vivo.

Authors:  Zhao-Qiang Zhang; Bo Shao; Gui-Zhi Han; Gen-Yi Liu; Chun-Zhi Zhang; Li Lin
Journal:  J Toxicol Pathol       Date:  2019-08-10       Impact factor: 1.628

Review 9.  TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019.

Authors:  Bedair Dewidar; Christoph Meyer; Steven Dooley; And Nadja Meindl-Beinker
Journal:  Cells       Date:  2019-11-11       Impact factor: 6.600

10.  Soluble Fraction from Lysate of a High Concentration Multi-Strain Probiotic Formulation Inhibits TGF-β1-Induced Intestinal Fibrosis on CCD-18Co Cells.

Authors:  Francesca Lombardi; Francesca Rosaria Augello; Paola Palumbo; Elona Mollsi; Maurizio Giuliani; Anna Maria Cimini; Maria Grazia Cifone; Benedetta Cinque
Journal:  Nutrients       Date:  2021-03-09       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.